OBP Ondine Biomed

 
TIDMOBP 
 
Ondine Biopharma Announces Private Placement Equity Financing 
FOR:  ONDINE BIOPHARMA CORPORATION 
 
TSX, AIM SYMBOL:  OBP 
 
April 6, 2010 
 
Ondine Biopharma Announces Private Placement Equity Financing 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 6, 2010) - 
 
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES 
 
Ondine Biopharma Corporation (TSX:OBP)(AIM:OBP) (the "Company") a medical technology company developing 
photodisinfection based products today announced it has issued 12,530,000 Units for gross proceeds of C$0.75 
million under a tranche (the "Tranche") of a non-brokered private placement (the "Placement") of up to 
13,800,000 Units for aggregate gross proceeds of C$0.83 million to qualified investors pursuant to applicable 
exemptions. Each Unit has a price of $0.06 and consists of one common share of the Company and one share 
purchase warrant (a "Warrant") entitling the holder to acquire one common share of the Company at an exercise 
price of $0.075 for a one year period from closing. 
 
Under the Tranche the Company issued 12,530,000 common shares and 12,530,000 Warrants expiring April 5, 2011. 
An application has been made for the 12,530,000 common shares issued under the Tranche to be admitted to 
trading on AIM ("Admission"), and Admission is expected to occur on or about April 12, 2010. The common shares 
issued under the Tranche and the common shares issuable on exercise of the Warrants issued under the Tranche 
are subject to a regulatory hold period in Canada expiring August 6, 2010. 
 
Pursuant to regulatory requirements, the Company has until April 23, 2010 to complete the remaining 1,270,000 
Units available under the Placement. Completion of subsequent closings can not be assured and are subject to 
certain conditions including, but not limited to, the receipt of all necessary approvals. 
 
Ms. Carolyn Cross, Ondine's Chairman and CEO, participated in the Placement, purchasing 1,500,000 Units (11.97% 
of the total units subscribed for in the Tranche). Ms. Cross, members of her immediate family and the Courthill 
Foundation, a charitable foundation in which Ms. Cross and her husband are directors, have a beneficial 
interest in an aggregate of 19,721,133 common shares, which represents 16.02% of the Company's 123,078,457 
issued and outstanding common shares (the "Enlarged Share Capital") immediately following the closing of the 
Placement (19.89% assuming exercise of 975,000 stock options and 4,959,091 warrants held by Ms. Cross). 
 
Ms. Margaret Shaw, a director of the Company, participated in the Placement, purchasing 170,000 Units (1.36% of 
the total units subscribed for in the Tranche). Ms. Shaw has a beneficial interest in 582,940 commons shares 
(0.47%) of the Enlarged Share Capital. 
 
Mr. Michael Crane, a director of the Company, participated in the Placement, purchasing 420,000 Units (3.35% of 
the total units subscribed for in the Tranche). Mr. Crane has a beneficial interest in 430,500 common shares 
(0.35%) of the Enlarged Share Capital. 
 
Other insiders of the Company participated in the Placement by purchasing a combined total of 340,000 Units 
(2.72% of the total units subscribed for in the Placement). 
 
The sale of the Units to insiders constitutes a "related party transaction" pursuant to Canadian securities 
regulation. However, the transaction is exempt from applicable formal valuation and minority shareholder 
approval requirements as neither the fair market value of the Units issued to insiders nor the consideration 
paid by such insiders for the Units exceeds 25% of the market capitalization of the Company. The material 
change report in respect of this transaction was not filed at least 21 days in advance of the closing of the 
Placement as the Company was in need of the funds. The Company considers the shortened timeframe to be 
reasonable under these circumstances. 
 
Ms. Cross's, Ms. Shaw's and Mr. Crane's participation in the Tranche constitutes a related party transaction 
for the purposes of the AIM Rules for Companies (the "Related Party Transactions"). Accordingly, the directors 
of the Company (excluding Ms. Cross, Ms. Shaw, and Mr. Crane), having consulted with its nominated adviser, 
consider the terms of the Related Party Transactions to be fair and reasonable insofar as the Company's 
shareholders are concerned. 
 
The total number of voting rights attached to the Enlarged Share Capital on the basis of one vote per common 
share is 123,078,457. This voting rights figure may be used by shareholders of the Company as the denominator 
for the calculations by which they will determine whether they are required to notify their interests in, or a 
change to their interest in, the Company under the Disclosure and Transparency Rules of the Financial Security 
Authority (FSA) in the United Kingdom. 
 
This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the 
securities in the United States. The securities have not been and will not be registered under the U.S. 
Securities Act or any state securities laws and may not be offered or sold within the United States unless 
registered under the U.S. Securities Act and applicable state securities laws or an exemption from such 
registration is available. 
 
About Ondine Biopharma Corporation 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and 
viral infections. The Company is focused on developing leading edge products utilizing its patented light- 
activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the 
formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, 
with a research and development laboratory in Bothell, Washington, USA. For additional information, please 
visit the Company's website at: www.ondinebiopharma.com. 
 
Forward-Looking Statements: 
 
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and 
other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. 
Factors that could cause actual results to differ materially from those projected in the Company's forward- 
looking statements include the following: market acceptance of our technologies and products; our ability to 
obtain financing; our financial and technical resources relative to those of our competitors; our ability to 
keep up with rapid technological change; government regulation of our technologies; our ability to enforce our 
intellectual property rights and protect our proprietary technologies; the ability to obtain and develop 
partnership opportunities; the timing of commercial product launches; the ability to achieve key technical 
milestones in key products and other risk factors identified from time to time in the Company's public filings. 
 
-30- 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biopharma Corporation 
Carolyn Cross 
Chairman and Chief Executive Officer 
(604) 669-0555 
ccross@ondinebiopharma.com 
www.ondinebiopharma.com 
 
OR 
 
Canaccord Adams Ltd. 
Ryan Gaffney 
Nominated Adviser 
+4420 7050 6500 
 
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this 
release. 
 
 
 
 
Ondine Biopharma Corporation 
 

Ondine Biomed (LSE:OBP)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024

Ondine Biomed (LSE:OBP)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024